Basilea’s Cresemba Enters Pediatric Trials in Japan via Asahi Kasei Partnership
Event summary
- Asahi Kasei Therapeutics initiated a Phase 2 clinical study for Cresemba (isavuconazole) in pediatric patients in Japan.
- The study focuses on safety and pharmacokinetics for children at risk of deep mycoses.
- Cresemba is already approved for pediatric use in the US, Canada, Europe, and China but not yet in Japan.
- Global sales of Cresemba reached USD 782 million in the year ending March 2026, up 27% YoY.
The big picture
Basilea’s expansion into pediatric antifungal treatment in Japan aligns with the growing demand for specialized therapies in immunocompromised children. The partnership with Asahi Kasei Therapeutics underscores the strategic importance of regional collaborations in scaling global sales, particularly in high-growth markets like Japan. Cresemba’s 27% YoY revenue growth highlights its dominance in the branded antifungal space, but sustaining this momentum will depend on successful pediatric approvals and continued market penetration.
What we're watching
- Regulatory Approval
- Whether the Phase 2 trial results will support pediatric approval in Japan, expanding Cresemba’s market reach.
- Revenue Growth
- The pace at which Cresemba’s global sales can sustain its 27% YoY growth trajectory.
- Competitive Dynamics
- How Basilea’s partnership with Asahi Kasei Therapeutics positions Cresemba against existing antifungal treatments in Japan.